All In Biotech

NDA 050819 · Bausch

Acanya

Benzoyl Peroxide, Clindamycin Phosphate · Topical

Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Oct 23, 2008

Approved uses

2

Original approval plus efficacy supplements

Registered trials

162

44 Phase 3, 7 recruiting

FAERS reports

309

79 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 15, 2025.

Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/3.75% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Clindamycin Phosphate and Benzoyl Peroxide Gel is a combination of clindamycin phosphate (a lincosamide antibacterial) and benzoyl peroxide indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. ( 1 )

Mechanism: Clindamycin: Clindamycin is a lincosamide antibacterial [see Microbiology (12.4) ] . Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects but the precise mechanism of action is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ACANYA · BENZOYL PEROXIDE 2.5%; CLINDAMYCIN PHOSPHATE EQ 1.2% BASE · GEL, TOPICAL · Prescription · TE AB
  • ONEXTON · BENZOYL PEROXIDE 3.75%; CLINDAMYCIN PHOSPHATE EQ 1.2% BASE · GEL, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Benzoyl Peroxide" as an intervention, any sponsor and status, largest first.

All 162 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective35
  • erythema26
  • acne25
  • pruritus25
  • rash22
  • dry skin18
  • expired product administered16
  • nausea12
  • skin discolouration12
  • burning sensation11
  • diarrhoea11
  • dizziness11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20103
20111
20126
201412
201555
201669
201751
201832
201921
202021
20215
20228
202311
20244
20251
20269

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Acanya (Clindamycin Phos/Benzoyl Perox)

2024 spending

$6K

Beneficiaries

n/a

12 claims

Per beneficiary

n/a

$9.27 per unit

View as table
YearSpending
2020$33,712
2021$15,965
2022$9,929
2023$14,030
2024$5,561

Part D: Onexton (Clindamycin Phos/Benzoyl Perox)

2024 spending

$63K

Beneficiaries

38

89 claims

Per beneficiary

$1,656

$13.83 per unit

View as table
YearSpending
2020$274,972
2021$348,412
2022$405,573
2023$414,937
2024$62,934

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 363 on PubMed

Sponsor: Bausch · Also marketed as Onexton

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.